Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting β2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

However, some of the studies raised concerns regarding increased risk of pneumonia related to regular use of ICS in adult patients with chronic obstructive pulmonary disease. A study findings published in the Respirology Journal: 2013, revealed an increased risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma regularly taking ICS. This could potentially lead to restrict application of ciclesonide by patients during the forecast period.              

Market Dynamics

Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2018, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.

Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

Key features of the study:

• This report provides in-depth analysis of ciclesonide market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2019 – 2026), considering 2018, as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global ciclesonide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study includes AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics.
• The global ciclesonide market report caters to various stakeholders in this industry including investors, researchers, ciclesonide manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the ciclesonide market.

Detailed Segmentation:

• Global Ciclesonide Market, By Indication:
• Allergy Rhinitis
• Asthma
• Global Ciclesonide Market, By Dosage Form:
• Aerosol
• Nasal Spray
• Global Ciclesonide Market, By Geography:
• North America
• By Country:

• U.S.
• Canada

• By Indication:

• Allergy Rhinitis
• Asthma
• By Dosage Form:

• Aerosol
• Nasal Spray

• Europe
• By Country:

• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

• By Indication:

• Allergy Rhinitis
• Asthma
• By Dosage Form:

• Aerosol
• Nasal Spray

• Asia Pacific
• By Country:

• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific

• By Indication:

• Allergy Rhinitis
• Asthma
• By Dosage Form:

• Aerosol
• Nasal Spray

• Latin America
• By Country:

• Brazil
• Mexico
• Argentina
• Rest of Latin America

• By Indication:

• Allergy Rhinitis
• Asthma
• By Dosage Form:

• Aerosol
• Nasal Spray

• Middle East
• By Country:

• GCC
• Israel
• Rest of Middle East

• By Indication:

• Allergy Rhinitis
• Asthma
• By Dosage Form:

• Aerosol
• Nasal Spray

• Africa
• By Country:

• North Africa
• Central Africa
• South Africa

• By Indication:

• Allergy Rhinitis
• Asthma
• By Dosage Form:

• Aerosol
• Nasal Spray

• Company Profiles
•  AstraZeneca Plc*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments
• Strategies
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.

“*” marked represents similar segmentation in other categories in the respective section.